Interim report
Page 1
Date of submission: October 30, 2026 To, The Secretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code – 539551 (EQ), 975516 & 976418 To, The Secretary Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051 Scrip Code- NH Dear Sir/Madam, Sub: Outcome of the Board Meeting held on October 30, 2026 Pursuant to Regulation 30 read with Regulations 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we wish to inform you that the Board of Directors of the Company at its meeting held today, i.e. October 30, 2026 (Friday) inter alia, has approved the unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026 together with the Limited Review Report reviewed by the Audit Committee and approved by the Board of Directors. A copy of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026 together with Limited Review Report is enclosed as Annexure- I for your information. The meeting of the Board of Directors commenced at 03:30 P.M. IST and ended at 05:50 P.M. IST. This is for your information and records. Thanking you, Yours faithfully For Narayana Hrudayalaya Limited Sridhar S. Group Company Secretary, Legal & Compliance Officer Encl.: as above .... .. Narayana Health Narayana Hrudayalaya Limited GIN: L8511 0KA2000PLC027497 Registered Office Address: 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru - 560099 Corporate Office Address: 9th & 8th Floor, Plot No. 84, Phase 1, West Avenue-1 , Electronics City, Bengaluru - 560100 Tel +91 80500 09318 J Website: www .narayanahealth.org ~Email : ~ info@narayanahealth.org
Page 2
Regd Office :31st Floor, Tower 3, One International Center, Senapati Bapat Marg, Elphinstone Road (West), Mumbai 400013 Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds Bengaluru 560 001 Karnataka, India Tel: +91 80 6188 6000 Fax: +91 80 6188 6011 INDEPENDENT AUDITORS REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF NARAYANA HRUDAYALAYA LIMITED 1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of NARAYANA HRUDAYALAYA LIMITED (the Company), for the quarter and six months ended September 30, 2026 (the Statement), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Listing Regulations). 2. This Statement, which is the responsibility of the Companys Management and approved by the Companys Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Companys personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. For DELOITTE HASKINS & SELLS LLP Chartered Accountants (Firms Registration No. 117366W/W-100018) Sathya P. Koushik Partner (Membership No. 206920) UDIN: 26206920SHSAOK2063 Place: Bengaluru Date: October 30, 2026 SPK/SG/TG/AB/2026 Annexure-1 Deloitte Haskins & Sells LLP SATHYA PRAMOD KOUSHIK Digitally signed by SATHYA PRAMOD KOUSHIK Date: 2026.10.30 17:08:21 +05'30'
Page 3
SI. No. 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. Narayana Hrudaya laya limited Registered office: No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 560099, Karnataka, India Corporate office : 8th & 9th ~loor, No. 84, Phase 1, West Avenue -1, Electronics Qty, Sengaluru, 560100, Karnataka, India CIN: l85110KA2000PLC027497, Website: www.narayanahealth .org, Email: investorrelations@narayanahealth.org STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS mR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2026 (~ in million e.cept per share data) Quarter ended Six months ended Year Ended Particulars 30-Sep-26 30-Jun-26 30-Sep-25 30-Sep-26 30-Sep-25 31-Mar-26 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) Income (a) Revenue from operations 11,853.77 10,971.02 10,191 .69 22,824 .79 19,623.10 39,751.41 (b) Oth er iricome (refer note 4) 433.50 304.13 170.88 737.63 335.24 1,764.34 Total income 12,287.27 11,275.15 10,362.57 23,562 .42 19,958.34 41,515.75 Expenses (a) Purchases of medical consumables, drugs, surgical instruments and 2,773.33 2,599.81 other consumables 2,355.76 5,373.14 4,567.07 9,134.03 (b} Changes in inventories of medical consumables, drugs, surgical (20.32) (29.77) instruments and other consumables - (Increase) / Decrease 11.00 (50.09) 39.29 30.53 (c) Employee benefits expense 1,964.18 1,912.19 1,804 .35 3,876 .37 3,565.90 7,053.80 (d) Professional fees to doctors 2,335.50 2,201.89 2,012.09 4,537.39 3,947.71 8,189.31 (e) Other expenses 2,188.97 1,895.68 1,717 .98 4,084.65 3,422.44 6,949.26 Expenses before depreciation and amortisation, finance costs and exceptional items 9,24L66 8,579.80 7,901.18 17,821.46 15,542.41 31,356.93 Earnings before depreciation and amortisation, finance costs and exceptional items (1-2) (EBITOA) 3,045.61 2,695.35 2,461.39 5,740.96 4,415.93 10,158.82 Finance costs 352.30 336.66 285.78 688.96 592.01 1,271.16 Depreciation and amortisation expense 501.09 481.48 462.66 982.57 938.24 1,914.78 Total expenses (2<4+5) 10,095.05 9,397.94 8,649 .62 19,492.99 17,072.66 34,542.87 Profit before tax and exceptional items (1-6) 2,192.22 1,877.21 1,712.95 4,069.43 2,885.68 6,972.88 Exceptional item (refer note 8) - (452.76) Profit before tax (7+8) 2,192.22 1,877.21 1,712.95 4,069.43 2,885.68 6,520.12 Tax expense (a) Current tax •Current year 418.93 481.11 315.79 900.04 602.40 1,564.92 (b) Deferred tax charge/(credit) 17.03 17.55 18.36 34.58 30.77 (75.93) Total tax expense 435.96 498.66 334.15 934.62 633.17 1,488.99 Net Profit for the period/ year (9-10) 1,756.26 1,378.55 1,378.80 3,134.81 2,252.51 5,031.13 Other comprehensive income Items that will not be reclassified subsequently to profit or loss (i) Re-measurement gains/(losses) on defined benefit plans 13.38 (46.38) 4.13 (33.00) (3.51) 9.45 (ii) Income tax effect (3.36) 11.67 (1.04) 8.31 0.88 (2.38) Items that will be reclassified subsequently to profit or Joss (i) Effective portion of gains/ (losses) in cash flow hedge 0.39 2.12 (6.90) (ii) Income tax effect (0.09) (0.53) - Other comprehensive income/ (loss), net of taxes 10.02 (34.71) 3.39 (24.69) (1.04) 0.17 Tota l comprehensive income/ (loss) for the period/year (11+12) 1,766. 28 1,343.84 1,382.19 3,110.12 2,251.47 5,031.30 Paid-up equity share capital (Face value of a: 10 each) 2,043.61 2,043.61 2,043.61 2,043.61 2,043.61 2,043.61 Reserves (Other Equity) - 23,930.71 Earnings/ (loss) per share not annua lised not annuali sed not annualised not annualised not an nualised annualised (of ~ 10 each) : (a) Basic 8.65 6.79 6.79 15.44 11.09 24.77 (b) Diluted 8.65 6.79 6.79 15.44 11.09 24.77 See accompanying notes to the unaudited standalone financial results
Page 4
J Notes: Narayana Hrudayalaya Limited Registered office: No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 560099, Karnataka, India Corporate office: 8th & 9th Floor, No. 84, Phase 1, We~t Avenue-1, Electronics Clty, Bengaluru, 560100, Karnataka, India CIN: L85110KA2000PLC027497, Website: www.narayanahealth.org, Email: lnvestorrelatlons@narayanahealth.org 1 The Statement of unaudited standalone financial results ('the Statement') for the quarter and six months ended 30 September 2026 of Narayana Hrudayalaya Limited ('the Company') has been reviewed by the Audit, Risk and Compliance Committee and approved by the Board of Directors of the Company at their respective meetings held on 30 October 2026. The statutory auditors have expressed an unmodified review conclusion on the unaudit ed standalone financial results for the quarter and six months ended 30 September 2026. The aforesaid results along with limited review report of the statuto ry auditors on the unaudited standalone financial result s for the quarter and six months ended 30 September 2026, is being filed with the National Stock Exchange of India Limited ('NSE') and BSE Limited ('BSE') and is also available on the Company's website. 2 The Statement has been prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standard ('Ind AS') 34 'Inter im financial reporting' prescribed under Sec'tion 133 of the Companies Act, 2013 read with t he relevant rule s issued thereunder and other accounting principles genera lly accepted in India and in compliance with Regulation 33 and 52 of the SEBI (Listing Obligaticns and Disclosure Requirements) Regulations, 2015, as amended. 3 The Company's operating segment is 'Medical and Healthcare Related ScrvicP.s'. Since the Company has a single operating segment, disclosure pertaining to segments as per Regulation 33(1)(e) read with clause (L) of Part A of Schedule IV of the SEBI Regulations is not applicable. 4 Other income for the year ended 31 March 2026 includes dividend income from Health City Cayman Islands limited (HCCI), wholly owned subsidiary amounting to ~ 943.52 million. 5 The Board of Directors of the Company had recommended a final dividend of" 4.50 per equity share of'( 10 each amounting to" 919.62 million for the year ended 31 March 2026, which was approved at the Annual General Meeting of the Company held on 14 August 2026. The aforesaid dividend was paid during the quarter. 6 The Board of Directors of the Company at its meeting held on 29 November 2024 approved the Scheme of Arrangement for the Merger of Meridian Medical Research & Hospital Ltd. ('MMRHL'), the subsidiary ('Transferor Company') with the Company ('Transferee Company') and their respective Shareholders and Creditors under Sections 230 to 232 and othe r applicab le provisions of the Companies Act, 2013 ('the Scheme') with 1 April 2024 as the appointed date and have recommended 1 (One) equity share of the Company to the shareholders of MMRHL (other than tile Company) for every 2 (Two) fully paid-up equity shares of MMRHL. The Stock Exchanges, SSE and NSE, after reviewing the Scheme filed with them by the Company on 20 December 2024 under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, had issued 'No Observation Letter' on 23 June 2025 and 24 June 2025, respectively under the said Regulations and the Scheme was filed with the Hon'ble National Company Law Tribun al, Bengaluru Bench (NCLT) on 27 September 2025. Pursuant to the Order dated 2 December 2025 issued by the Hon'ble NCLT, the meetings of the Creditors and the Shareholders cf the Transferor Company and the Transferee Company were held on 19 January 2026 who have passed the Scheme with more than requisite majority. Post approval by the Creditors and the Shareholders, a Petition along with the voting results has been filed with the Hon'ble NCLT on 23 January 2026. Notices were dispatched to all the Regulatory Authorities for seeking their 'No Objection' with respect to the merger of MMRHL with the Company. The Company has received No-Objection Letters from the Regulatory Authorities and basis the hearines, the Final Order by the Hon'ble NCLT is expected to be received in due course. Further, there is no impact on results for the quarter and six months ended 30 September 2026. 7 The Board of Directors of the Company at the meeting held on 12 December 2025 had approved the Scheme of Arrangement between NH Integrated Care Private Limited (NHIC) (Wholly Owned Subsidiary) ['Demerged Company'], Narayana Hrudayalaya ~imited ('Resulting Company') and their respective shareholders and creditors to demerge the clinical services as defined in the scheme of NHIC ('the Demerged Undertaking') into the Resulting Company, while continuing the Narayana Aarogyam Vertica l within NHIC, on a going concern basis under Sections 230 to 232 and othe r applicable provisions of the Companies Act, 2013 ('the Scheme') with 1 April 2025 as the Appointed Date. The Scheme was filed with the NCLT, Benealuru Bench on 17 December 2025. Pursuant to the Order dated 13 February 2026 issued by the Hon'ble NCLT, the meetings of the Creditors and the Shareholders of the Demerged Company and the Resulting Company were held on 2 April 2026 who have passed the Scheme with more than requisite majority. Post approval by the Creditors and the Shareholders, a Petition along with the voting results has been filed with the Hon'b le NCLT on 8 Apri l 2026. Ther~ will be no issuance of shares as consideration, in view of the Demerged Company being a wholly-owned subsidiary of the Resulting Company. The Company is in the process of obtaining the requisite No-Objection Certificates ('NOC') from the Regulatory Authorities. Upon receipt of No-Objection letters from the Regulatory Authorities and basis the hearings, the Final Order by the Hon'ble NCLT is expected to be received in due course.There is no impact on the financial results of the Company for the quarter and six months ended 30 September 2026. 8 On 21 November 2025, the Government of India _notified provis ions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Condition; Code, 2020 (collectively referred to as the 'Labour Codes'). These Labour Codes consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during and post-employment. The Labour Codes amongst other things introduced changes including a uniform definit ion of wages and enhanced benefit to leave. The Company had assessed the fina ncial implicat ions of these changes which had resulted in increase in gratuity liability and leave liability arising out of past service cost by 0:452.76 million for the year ended 31 March 2026. As the impact arises from the enactment of new legislation and is considered non-rec urring in nature, the Company has presented this incremental amount under 'Exceptional Item'. 9 The Standalone balance sheet as at 30 September 2026, the Statement of standalone cash flows and disclosure as per regulation 52(4) of SEBI (Listing obligations and disclosure requirements) regulations, 2015 are provided as annexures to this Statement . Place: Benga luru Date: 30 October 2026 for and on behalf of the Board of Directors of , • • - ~' . ,y Narayana Hrudayalaya Limited ' :.t.. \ I)) ' , r ,/j• -------~~· . 9 Dr. Emmanuel Rupert Managing Director & Group CEO
Page 5
Narayana Hrudayalaya limited Registered office: No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bengaluru 560099, Karnata ka, India Corporate office : 8th & 9th Floor, No. 84, Phase 1, West Avenue -1, Electronics City, Bengaluru, 560100, Karnataka, India CIN : L85110KA2000PLC027497, Website: www.nara yanahealt h.org, Email: investorre lations@naraya nahealth.org STANDALONE BALANCE SHEET (a: inmillion) SI. No. Particulars As at 30 September 2026 As at 31 March 2026 (Unaudited) (Audi ted) A. ASSETS 1. Non-current assets a) Property, plant and equipment 23,240.95 21,990.28 b) Capital work-in -progress 2,120.89 2,091.63 c) Right of use assets 1,478.08 1,399.93 d) Goodwill 220.59 220.59 e) Intangible assets 665.46 731.64 f) Intangible assets under development 234.55 250.94 g) Financial assets i) Investments 9,203.25 8,863.44 ii) Loans 5,131.26 6,009.49 iii) Other financial assets 653.75 620.11 h) Income tax assets (net) 15.12 15.12 i) Other non-current assets 811.72 692.47 Sub-tota l- Non-current assets 43,775.62 42,885.64 2. Current assets a) Inventor ies 454.88 404.78 b) Financial assets i) Investments 3,370.51 2,002.90 ii) Trade receivables 4,605.58 3,254.19 iii) Cash and cash equivalents 1,807.31 1,802.91 iv) Bank balances other than (iii) above 2,940.88 2,434.64 v) Loans 711.80 545.00 vi) Other financial assets 822.11 591.52 c) Other current assets 429.19 313.81 Sub-total- Current assets 15,142.26 11,349.7 5 TOTAL- ASSETS 58,917.88 54,235.39 B. EQUITY AND LIABILITIES 1. Equity a) Equity share capital 2,043.61 2,043.61 b) Other equity 26,126.88 23,930.71 Sub-tota l- Total equity 28,170.49 25,974.32 2. Non-current liabilities a) Financial liabilities i) Borrow ings 17,912.27 17,377.47 ii) Lease liabilities 1,268.37 1,174.60 iii) Other financial liabil ities 489.60 488.63 b) Provisions 718.73 677.83 c) Deferred tax liabilities (net) 505.36 479.09 d) Other non-current liabilities 332.34 352.65 Sub-tota l- Non-current liabilities 21,226.67 20,SS0.27 3. Current liabilities a) Financial liabilities i) Borrowings 1,398.08 1,007.97 ii) Lease liabilities 150.51 138.59 iii) Trade payables Total outstanding dues of micro enterprises and small enterprises 245.99 225.52 Total outstanding dues of creditors other than micro enterprises and small enterprises 5,197.59 4,173.38 iv) Other financial liabilities 630.72 418.01 b) Other current liabilities 751.54 740.38 c) Current tax liabilities (net) 450.06 249.86 d) Provisions 696.23 757.09 Sub-tota l- Current liabilities 9,520.72 7,710.80 TOTAL- EQUITY AND LIABILITIES 58,917.88 54,235.39
Page 6
Narayana Hrudayalaya Limited Registered office: No. 258/A, Bommasandra Industria l Area, Anekal Taluk, Bengaluru 560099, Karnataka, India Corporate office : 8th & 9th Floor, No. 84, Phase 1, West Avenue- I, Electronics City, Bengaluru, 560100, Karnataka, India CIN: l85110KA2000PlC027497, Website: www.narayanahealth .org, Email: investorre lations@narayanahea lth.org STATEMENT Of STANDALONE CASH FLOWS FOR SIX MONTiiS ENDED 30 SEPTEMBER 2026 Particulars Cash flow from operating activities Profit after tax Adjustments: Income ta,,; charge /(credit) Depreciation and amortisation Provision for loss allowance & doubtfu l advances Sad receivables written off Provisions no longer required written back Interest income Interest income from financial asset at amortised cost Finance costs Guarantee commission income Government grant income l oss and provision on disposal of assets Profit on safe of investment Unrealised foreign exchange (gain)/loss (net) Operating cash flow before working capital changes Changes in trade receivables Changes in inventories Changes in loans, other financial assets and other assets Changes In trade payables, other financial liabilities and other liabilities Changes in provision Cash generated from operations Income taxes (paid)/ refund received (net) Net cash generated from operating activities (A) Cash flow from invest ing activities Acquisition of Property, plant and equipment (including capital work-in-progress, Intangible assets and Intangible assets under development, capital advances and capital creditors) Proceeds from sale of property, plant and equipment Investment in other non~cu·rrent investment Investment in equity shares of subsidiaries loan given to subsidiaries Proceeds from redemption of Optionally Convertible Debenture lOCD) loan repaid by subsidiaries Investment in mutua l fund Proceeds from sale of mutual fund Investment in bank deposits Proceeds from bank deposits Interest received Net cash (used in} investing activities (B) Cash flow from financing activities Proceeds from long-term borrowings Repayment of long-term borrowin gs Dividend paid on equity share (net of dividend received on treasury shares and unclaimed dividend) Payment of Interest and other borro wing costs Payment of lease liabilities Net cash (used in] financing activities (C) Net increase/(decrease) in cash and cash equivalents (A-+-B•C} Cash and cash equivalents at the beginning of the period* Effects of exchange gain on restatement of foreign currency cash and cast, equivalents Cash and cash equivalents at the end of the period• • Cash and cash equivalents include bank overdrafts that are repayable on demand and form an integral part of the Company1s cash management. Cash and cash equivalents Particulars cash on hand Balance with banks -In current accounts -In deposit accounts (due to mature within 3 months of the acquisition date) Less: Bank overdraft used for cash management purposes• Cash and cash equivalents in the statement of cash flows • Cash and cash equivalents include bank overdrafts that are repayable on demand and form an integral part of the Company's cash management . Reconciliation of liabilities from financing activities for she months ended 30 September 2026 As at Particulars 1 April 2026 Proceeds Repayment Borrowings (including current maturities) 18,385.44 1,411.20 (486.29) lease liabilit ies 1,313.19 (126.73) Total liabilities from financing activities 19,698.63 1,411.20 (613.02) Reconciliation of liabilitie s from financing activities for six months ended 30 September 2025 Asal -P~rticuh.1:rs .,.....-,.,r1ftrn--...... 1April 2025 Proceeds Repayment Borrowings (including current maturities) l«,.r-~\ 14,758.89 1,513.13 (1,482.85) Lease liabilities 1,192.17 (131.05) Total liabilities from financing activities ,~, .... ·--- - - \'r- 15,951.06 1,513.13 (1,613.90) . ( . ' I ~oCCOUNTANTS§::::, y- I c::> "t, *~ \;)* • ~NGA\.'U~ -- For the period ended 30 September 2026 (Unaudited) 3,134.81 934.62 982.57 214.72 (19.10) (317.87) (17.89) 688.96 (6.07) (21.51) 9.75 (72.86) (23.25) 5,486.88 (1,562.55) (50.10) (13126) 1,042.27 (52.96) 4,732.28 (682.75) 4,049.53 (2,311.84) 33.60 (9.81) (330.00) (181.80) 953.79 15.00 (4,799.76) 3,505.01 (1,464.26) 950.51 63.24 (3,576.32) 1,411.20 (486.29) (913.26) (304.97) (126.73) (420.05) 53.16 1,802.91 (48.76) 1,807.31 Asat 30 September 2026 48.04 1,616.16 143.11 1,807.31 1,807.31 Non cash changes Fair value/ other changes Foreign exchange 232.42 232.42 Non cash changes Fair value/ other change$ Foreisn eM<:h:;mge 132.62 132.62 ('in million) for the period ended 30 Septembe r 2025 (Unaudited} 2,252.Sl 633.17 938.24 58.33 1.39 (7.61) (113.49) (16.52) 592.01 (5.46) (22.28) 17.94 (85.37) (9.32) 4,233.54 (524.69) 39.29 12.10 109.95 84.03 3,954.22 (611.75) 3,342.47 (1,566.51) 2.32 (70.00) (178.00) (7,350.00) 4,456.97 (256.29) 1,357.65 93.99 (3,509.87) 1,513.13 (1,482.85) (913.95) (199.15) (131.05) (1,213.87) (1,381.27) 2,480.03 5.08 1,103.84 (' in million) Asal 30 September 2025 64.20 714.21 325.93 1,104.34 (0.50) 1,103.84 (~ in million) Asal 30 September 2026 19,310.35 1,418.88 20,729.23 (~ in million} As •t 30 September 2025 14,789.17 1,193.74 \ 15,982.91
Page 7
\ SI. No. Narayana Hrudaya laya Limited Registered office: No. 258/A, Bommasand ra Industrial Area, Anekal Taluk, Bengaluru 560099, Karnataka, India Corporate office: 8th & 9th Floor, No. 84, Phase 1, West Avenue -1, Electronics City, Bengaluru, 560100, Karnataka, India CIN: L85110KA2000PLC027497, Website: www.narayanahea lth.org, Email: investorrelations@narayanaheal t h.org ADDITIONAL DISCLOSURES AS PER REGULATION 52(4) OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS] REGULATIONS 2015 Quarter ended Six months ended Particu lars 30-Sep-26 30-Jun-26 30-Sep-25 30-Sep-26 30-Sep-25 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) 1 Debt equity ratio 0.74 0.73 0.69 0.74 0.69 2 Debt service coverage ratio 4.03 3.63 3.35 3.83 2.83 3 Interest service coverage ratio 7.22 6.58 6.99 6.91 5.87 4 Current ratio 1.59 1.49 1.60 1.59 1.60 5 Long term debt to working capital ratio 2.75 3.35 2.79 2.75 2.79 6 Bad debts to accounts receivable ratio . - . 7 Current liability ratio 0.31 0.30 0.31 0.31 0.31 8 Total debt to total assets ratio 0.33 0.33 0.31 0.33 0.31 9 Debtors turnover rat io 2.80 3.08 3.48 5.81 7.20 10 Operating margin(%) 22.04% 21.80% 22.47% 21.92% 20.80% 11 Net profit margin(%) 14.82% 12.57% 13.53% 13.73% 11.48 % 12 Inventory turnover ratio 6.19 6.12 5.89 12.38 11.08 13 Capital redemption reserve/Debenture redemption reserve NA NA NA NA NA 14 Net worth [~ in million] 28,170.49 27,318.16 23,194.49 28,170.49 23,194.49 15 The Company has not issued any secured listed non-convertible debt securities * values are ms1gnificant Formulae for computation of ratios are as follows Formu lae Year Ended 31-Mar -26 (Audited) 0.76 3.31 6.13 1.47 3.96 . 0.27 0.34 13.84 21.12% 12.66% 21.82 NA 25,974.32 s.no Particulars Numerator Denominator 1 Debt equity ratio Debt consist borrowings and lease liabilities Total equity 2 Debt service coverage ratio Earnings for debt service=Earnings Before Interest Debt Service=Finance cost& lease and Tax payments+principal repayments (excluding prepayments and working capital loan) 3 Interest service coverage ratio Profit before taxes+finance cost Finance cost 4 Current ratio Total current assets Total current liabilities 5 long term debt to working capital ratio Long term borrow ings (including current maturities Current assets(-) Current liabilities of long term borrowings) [Excluding current maturit ies of long term borrow ings] 6 Bad debts to accounts receivable ratio Bad debts Average gross trade receivables 7 Current liability ratio Total current liabilities Total liabilities (without equity ) 8 Total debt to tota l assets rati o Total borrow ings Total assets 9 Debtors turno ver ratio Revenue from operations Average trade receivables 10 Operating margin( %) Earnings before depreciation, finance cost, tax and Revenue from operations exceptional items(-) Other Income 11 Net profit margin (%) Net profit after taxes Revenue from operat ions 12 Inventory turnover ratio Cost of goods sold= Purchase of medical Average Inventory consumables, dr ugs, surgical instrumen ts and other consumables+ Changes in inventories medical consumables, drugs, surgical instruments and other consumables
Page 8
Regd Office :31st Floor, Tower 3, One International Center, Senapati Bapat Marg, Elphinstone Road (West), Mumbai 400013 Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds Bengaluru 560 001 Karnataka, India Tel: +91 80 6188 6000 Fax: +91 80 6188 6011 INDEPENDENT AUDITORS REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF NARAYANA HRUDAYALAYA LIMITED 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of NARAYANA HRUDAYALAYA LIMITED (the Parent) and its subsidiaries (the Parent and its subsidiaries together referred to as the Group), and its share of the net loss after tax and other comprehensive loss of its associate and joint venture (including its subsidiary) for the quarter and six months ended September 30, 2026 (the Statement) being submitted by the Parent pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Listing Regulations). 2. This Statement, which is the responsibility of the Parents Management and approved by the Parents Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 Review of Interim Financial Information Performed by the Independent Auditor of the Entity , issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parents personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable. 4. The Statement includes the interim financial information of the entities listed in Annexure I. 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. Page 1 of 4 Deloitte Haskins & Sells LLP
Page 9
Page 2 of 4 6. We did not review the interim financial information of seven subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect total assets of Rs. 2178.86 million as at September 30, 2026, total revenues of Rs. 302.72 million and Rs. 626.98 million for the quarter and six months ended September 30, 2026, respectively, total net loss after tax of Rs. 127.50 million and Rs. 278.28 million for the quarter and six months ended September 30, 2026, respectively and other comprehensive loss of Rs. 0.19 million and Rs. 1.08 million for the quarter and six months ended September 30, 2026, respectively and net cash outflows of Rs. 99.33 million for the six months ended September 30, 2026, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of these matters. 7. The consolidated unaudited financial results includes the unaudited financial information of two subsidiaries (including one step down subsidiary), whose financial information reflect total assets of Rs. 148.11 Million as at September 30, 2026 and total revenues of Rs. Nil and Rs. Nil for the quarter and six months ended September 30, 2026, respectively, total net loss after tax of Rs. 0.04 Million and Rs. 0.06 Million for the quarter and six months ended September 30, 2026, respectively, and other comprehensive loss of Rs. Nil and Rs. Nil for the quarter and six months ended September 30, 2026, respectively, and net cash inflows of Rs. 2.13 Million for the six months ended September 30, 2026, as considered in the Statement. The consolidated unaudited financial results also includes the Groups share of loss after tax of Rs. 24.33 million and Rs. 43.09 million for the quarter and six months ended September 30, 2026, respectively and other comprehensive loss of Rs. Nil and Rs. Nil for the quarter and six months ended September 30, 2026, respectively, as considered in the Statement, in respect of one associate, one joint venture and one subsidiary of joint venture whose financial information have not been reviewed by us. These financial information are unaudited and have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, one associate, one joint venture and one subsidiary of joint venture, is based solely on such unaudited financial information. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial information are not material to the Group. Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management. Deloitte Haskins & Sells LLP
Page 10
Page 3 of 4 8. The actuarial valuation of liabilities on insurance policies in force, Claims Incurred but Not Reported (IBNR), Claims Incurred but Not Enough Reported (IBNER) and Premium Deficiency Reserve (PDR), recorded in the unaudited interim financial information of the Narayana Health Insurance Limited (NHIL) and Cayman Integrated Healthcare Limited (CIHL) for the quarter and six months ended September 30, 2026 has been duly estimated and certified by the respective Companys Appointed Actuary (the Appointed Actuary) and in their opinion, the assumptions for such valuation are in accordance with generally accepted actuarial principles, the requirements of the Insurance Act, 1938, Insurance Act (Amendment), 2015, and the Actuarial Practice Standards and Guidance Notes of the Institute of Actuaries of India in concurrence with the Insurance Regulatory and Development Authority of India and the Insurance laws of Cayman, as may be applicable. We have relied upon the certificate of the Appointed Actuary of CIHL and NHIL during our review of the valuation of liabilities in respect of insurance policies in force, IBNR, IBNER and PDR which are included in the unaudited consolidated financial results of the Group, its associate and joint venture (including its subsidiary). For DELOITTE HASKINS & SELLS LLP Chartered Accountants (Firms Registration No. 117366W/W-100018) Sathya P. Koushik Partner (Membership No. 206920) UDIN: 26206920BGPZIF8357 Place: Bengaluru Date: October 30, 2026 SPK/SG/TG/AB/2026 Deloitte Haskins & Sells LLP SATHYA PRAMOD KOUSHIK Digitally signed by SA THYA PRAMOD KOUSHIK Date: 2026.10.30 17:06:10 +05'30'
Page 11
Page 4 of 4 Annexure I - List of entities included in the Consolidated Financial Results: Sl. No. Entity Relationship 1. Narayana Hrudayalaya Limited (NHL) Parent 2. Narayana Hospitals Private Limited (NHPL) Subsidiary 3. Meridian Medical Research & Hospital Limited (MMRHL) Subsidiary 4. Narayana Vaishno Devi Specialty Hospitals Private Limited (NVDSHPL) Subsidiary 5. Narayana Hrudayalaya Surgical Hospital Private Limited (NHSHPL) Subsidiary 6. Health City Cayman Islands Limited (HCCI) Subsidiary 7. Narayana Health North America LLC Subsidiary 8. Medha AI Private Limited (MAPL) Subsidiary 9. Samyat Healthcare Private Limited (SHPL) Subsidiary 10. NH Integrated Care Private Limited (NHIC) Subsidiary 11. Narayana Health Insurance Limited (NHIL) Subsidiary 12. Athma Healthtech Private Limited (AHPL) Subsidiary 13. Narayana Healthcare North Private Limited (NHNPL) Subsidiary 14. Narayana Holdings Private Limited (NHDPL) Subsidiary of HCCI 15. Cayman Integrated Healthcare Limited (CIHL) Subsidiary of HCCI 16. ENT in Cayman Islands Limited (EICL) Subsidiary of HCCI 17. Narayana Hrudayalaya UK Ltd (NH UK) Subsidiary of HCCI 18. Reya Health Inc Associate of HCCI 19. Everhope Oncology Private Limited (EOPL) Joint venture of HCCI 20. Samvaya Oncology Private Limited (SOPL) Subsidiary of EOPL 21. NH Health Bangladesh Private Limited (NHHBPL) Subsidiary of NHDPL 22. Practice Plus Group Hospitals Limited (PPGHL) Subsidiary of NH UK 23. Practice Plus Group Property Limited (PPGPL) Subsidiary of NH UK 24. Shepton Mallet Health Partnership Limited (SMHPL) Subsidiary of PPGHL Deloitte Haskins & Sells LLP
Page 12
Naraya na Hrudayalaya Limited Regi stered offiec: No. 158/A, Bommasandr :1 Industrial Arca. Anekal Taluk, Bcnga lun1 560 099, K.trnat:,ka, Ind ia Corporate office: 8th & 9th Floor, No. 84, Phase 1, West Avenue -1, Electron ics City, Beng.1luru - 560100, Karnataka, India ClN : L851 l0KA2000PLC02749 7, \Vebsite: www.narayanahcalth .org, Email: investorrcl:ltioo s@n:1rayanahealth .org STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AN D SIX MONTHS ENDED 30 SEPTEMBER 2026 (tin Million, except oer share data ) Quarter ended Six months ended Year ended SI. Parti culars 30.Sen-26 30-Jun -26 30.Sc<>-25 30-Seo-26 30.Seo-25 31-Mar-26 No. (Unaudited) (Unaudi ted) (Unaudited) (Unaudited) (Unaudited) (Audited) Continuing operati ons 1. Income (a) Revenue from operations 28,439.89 26,836.34 16,437.90 55,276.23 31,510 59 78.960 35 (b) Other mcome 515.42 354 76 239 92 870 18 477 84 1,002 19 Tota l income 28,955.3 1 27,191.10 16,677.82 56,146.4 1 31,988.43 79,962.54 2. Expenses (a) Purchases of medical consumables, drugs, surgical instruments and other consumables 5,541.60 5,203 06 3.229 60 10,744 66 6,283 59 15,603.8 1 (b) Changes m mvcntones of medical consumables, drugs, surg1caJ instruments and other (65 08) (60 24) (7.36) (125.32) (3 25) (442.68) consumables - (lncrease} / Decrease (c) Employee benetitS expense 7.358 67 7.248.38 2.990 92 14.607 OS 5,946.15 18,029 81 (d) PrQfcssional fees to doctors 3,432 36 3,270 10 2,548.66 6,702.46 4,99044 10.987 38 lte) Other exnenses 6.633.61 6.478 02 3.65 I 07 13, 111 63 6.899 14 18.615.31 Exncnscs before depr ec-intion and amortisation , finance costs and exccotlooal items 22,901.16 22,139.32 12,4)2.89 45,040.48 24,116 .07 62,793.63 3. Earn ings befor e depreciation and amortis:,tion. finance costs and exceptional items 6,054.15 S.0S!.78 4,264.93 11,105.93 7,872.36 17,168.91 111-21 /l'BITDA l 4 Finance costs 967.19 868 01 422 60 1,835 20 874.23 2.437 41 5. Deorec1at1on and amortisation expense 1,629.49 1,560 81 874,76 3, 190 30 1,717 78 4.478 02 6. Tot:il Exoenses (2+4+51 25,497.84 24,568.14 13,710.25 50,065.98 26,708.08 69,709.06 7• Profit before sh:.1re ofloss or equity accounted investees, tu nnd exceptional items (1-6) 3,457.47 2,622.96 2,967.57 6,080.43 5,280.35 10,253.48 8 Exccotional item (Refer Note 8) - (509.54) 9. Profit before share of loss of eau ity ac-counted investees and income tax (7+8) 3,457.47 2,622.96 2,967.57 6,080.43 5,280.35 9,743.94 IO. Share of loss of eau,ty accounted investees (24 02) (19 07) (12 75) (43 09) (17 16) (55,79) 11. Profit before tax (9+10) 3,433.45 2,603.89 2,954.82 6,037.34 5,263.19 9,688.15 12. Tax exoense lta) Current tax -Current nenod/vear 493.33 557.03 362.31 1,050 36 703.96 1,766 04 (b) Deferred tax char~e/(cred1t) (7141) (25 84) 9 62 (97 25) 15.83 (18248) Total t:ix c>:pcnses 421.92 531.19 371.93 953.11 719.79 1,583.56 13. Net Profi t for the period/ year from continuing opcr!ltions (11-12) 3,0ll.53 2,072.70 2,582.89 5,084.23 4,543.40 8,104.59 14. Discontinued Onerations (Refer Note 6\ Profit/ (Joss) before tax from discontinued operations 2.06 9 31 25 17 Tax exoense of discontinued ooerahons (0.69) (7.91) Loss on disoosal of discontinued ooerauons - (6206) Profit/lloss\ for the neriod/ vcar from disro11ti11ued oucrations after taxes - - 2.06 - 8.62 144.80) 15. Other comprehensive income from continu ing operations liems Iha/ will 1101 be reclassi/if:d sub.Ieque~ulv to profit or loss f1l Re-measurement ~ams/ (losses) on defined benefit ol.ms 10.8l I (52.54) 4.22 (41 73) (7 18) 9 44 (ii) Income tax effect (3 59) 11.79 (1.16) 8.20 0.97 (3 09) {iii) Eauitv instruments throu2.h other comorchens1vc mcome. net (1 01) (12.31) (22.26) (l3 32) (1 73) (22.96) items 1ha1 w,I/ be reclassified subsequently to profit or loss fi) Effective nort1on of ~ains/ (losses) m cash flow hedt!es 269.92 (79 63) 0,39 19029 212 (6.90) fu) Income tax effect (0,09) (0.53) (iii) Effective ponion of gains/ (losses) of net investment hedge ma foreign operation 2.38 209 (7.76) {iv) Exchan2c differences in tr.'mslatin~ the financial statement offoreiirn ooerations 344.83 0.44 711 01 345.27 703 33 1,998 47 Other comnrehensive income/ llossl, net of taxes from continuint operations 620.96 (132.251 694.49 488.71 699.07 1,967.20 16. Other comprehen sive income from discont inued operations (Refer Note 6) Items Jhal will nol be rec/a:'iSl/ied subsequently to profit or loss (i) Re-measurement £ams/ (losses) on defined benefit olans (0.52) (0 54) (0.18) (i i) Income tax effect - Other comnrchcn sivc income/ (loss\, net of taxes from discont inued operations - (0.52) - (0.54) (0.18) 17. Tota l compre bensive"incomc (13+14+15 +16) 3,632.49 1,940.45 3,278.92 5.572.94 5,250.55 10,026.8 1 18. Nel Profit attrib utable to: Owners of the company 3,010.27 2.071.78 2.583.71 5,082 05 4.550.22 8.055 99 Non-controllmg interests 1.26 0,92 l 24 218 1 80 J 80 Net Profit for the period/ year 3,011.53 2,072.70 2,584.95 5,084.23 4,552.02 8,059.79 19. Other comorehen sive income/ (loss) attr ibutable to: Owners of the company 620.96 (132 25) 693.97 488 71 698 51 1.966.99 Non-controlling interests 0.02 O.oJ Other comorebeosive income/ (loss) for the oeriod/ vear 620.96 (132.25) 693.97 488.71 698.53 1,967.02 20. Tot:d comprehe nsive income attributab le to: Owners of the companv 3.631.23 1,939 53 3.277 68 5.570 76 5,248 73 10,022.98 Non-controlling interests 1 26 0.92 I 24 2.18 1.82 3 83 Total comprehensive income for the period/ year (18+19) 3,632.49 1,940.45 3,278.92 5.572.94 5,250.55 10,026.81 21. Paid-up equity share capital 2,043 61 2.043 61 2.043 61 2,043.61 2,043 61 2.043.61 (Face value of~ IO each) 22. Reserves (Other Eauitv) 43,328.97 23. Earnmgs per share (for contmumg operations) not annualised not annualised not annualised not annualised not annualised annualised (of~ IO each) (a) Bas,c 14 82 1020 12.71 25 02 22 36 39 89 (b) D1lu1ed 14.82 10.20 12 71 25 02 22.36 39 89 Earnings per share (for d1scontmued operations) not annualised not annualised n~t annualised not annualised not annualised armuahsed (of { IO each) (a) Basic 0,01 004 (0.22) (b) Diluted 0 01 004 (0.22) Earnrngs per share (for contmumg and d1scontmued operations) not annualised not annualised not annualised not annuahsed not annuahsed annualised (of { 10 each) '1 ~ ,,,. ~ ;-~967 (a) Ba.•.ic 14 82 10 20 12 72 25 02 p~o, (b) Diluted 1451 I0ZO IZ 7Z 25 oz : 22.40 \ ·-· --."' ..._ , J9 7 See accompanying notes to the unaudited consolidated financial results f!::::f A u ---- .~ I ' ~- '. \ I id ACCOUNTAN~S '~l I • ' ' , C' ,-.. \ . · : l \ * *l> ·-, \ . • !
Page 13
r \ Narayana Hrudayalaya Limited Registered office: No. 258/A, Bommasandra Industrial Area, Anekal Taluk, Bcngaluru 560 099, Karuataka, lnclia Corl'orate office :8th & 9th Floor, No. 84, Phase l, West Avenue - I, Electronics City, Bengaluru -560100, Karnataka, India CIN : L85110KA2000PLC027497, Website: www.narayanahealth.org, Email: invcstorrelations fa,lnarayanahealth.org STATEi\lENT OF UNAUDITED CONSO LIDATED FINANCIAL RESULTS FOR THE QUARTER AND SU{ MONTITS ENDED 30 SEPTEMBER2026 Notes: I The Statement of unaudited consolidated financial results ('the Statement') for the quarter and six months ended 30 September 2026 of Narayana Hrudayalaya Limited (the 'Parent' / 'Company'), its subsidiaries (together referred to as the 'Group') and its share of loss in associate/Joint venture (including its subs1d1ary) has been reviewed by the Audit, Risk and Compliance Committee and approved by the Board of J.)irectors of the company at their respective meetings held on 30 October 2026. The Statutory Auditors have expressed an unmodified review conclusion on the unaudited consolidated financial results for the quarter and six months ended 30 September 2026. The aforesaid results along with limited review report of the Statutory Auditors on the unaudited consolidated financial results for the quarter and six months ended 30 September 2026. is being filed with the National Stock Exchange of India Limited ("NSE") and BSE Limited and is also available on the Company's website. 2 The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ("'IND AS'") 34 'Interim financial reporting' prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 3 The Board of Directors of the company had recommended a final dividend on 4.50 per equity share oH JO each amounting tot 919.62 million for the year ended 31 March 2026, which was approved at the Annual General Meeting of the company held on 14 August 2026, the aforesaid dividend was paid during the quarter. 4 Segment Information The Group's operating segments are 'Medical and Healthcare Related Services' and Others (Insurance Segment) and the disclosure pertaining to segments as per Regulation 33( l)(e) read with clause (L) of Part A of Schedule IV of the SEBI Regulations has been given below. a) Segment revenues and results. (tin Million) Quarter ended Six months ended Year ended SI. No. Particu lars 30-Sep-26 30-Jun-26 30-Sep-25 30-Sep-26 30-Sep-25 31-Mar-26 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) l Segment Revenue a )Revenue from operanons Medical and healthcare related services I 26.864.32 25.403.49 16.098 60 52.267 81 31,169.22 76,886 87 Others 1,738 95 1,563 56 844 85 3,302 51 1,303.43 3.856 50 Less Inter segment revenue (163 38) (130.7 1) (11 1 28) (294 09) (208 43) (405 65) Total revenue from operations (a) 28,439.89 26,836.34 16,832.17 55,276.23 32,264.22 80,337.72 Unallocaled other mcome '" '(b) 51542 354 76 240 84 870 18 480.18 1.cxn .02 Total income (a)+(b) 28,955.31 27,191.10 17,073.01 56,146.41 32,744.40 81,344.74 2 Segment Result Medical and healthcare related services 1 4,242 89 3,741 75 3,303 86 7.984 64 6,072 23 12.386 22 Others (357.67) (624.6 1) ( 164 79) (982 28) (405 25) (1.241 90) 3.885 22 3,1 17 14 3.139 07 7.002 36 5,666 98 11,144 32 Add. Unallocated other income 1 11: J 51542 354 76 240 84 870 18 480 18 1.007 02 Less· Finance cost 1 967. 19 868 0 1 423 03 1,835 20 87466 2,438 02 Profit befor e ta,:cs 3,433.45 2,603.89 2,956.88 6,037.34 5,272.50 9,713.32 3 Segment Assets Medical and healthcare related services 2 1,06,445 96 1.02.443 72 60,549.15 1.06,445 96 60,549 15 1,03,2 17 89 Others 3.737 89 3,427 17 1.96461 3,737 89 l.96461 3,085 16 Unallocated 3 23,489.76 21.853.69 14.905.97 23,489 76 14.905 .97 18,440.99 Total 1,33,673.61 1,27,724.58 77,419.73 l,33 ,673.61 77,419.73 l,24 ,744.04 4 Segment Liabilities Medical and healthcare related services 2 27,604 62 25,672 35 13,291.81 27,604 62 13,291 81 25.351.66 Others 1.673.98 1.620 00 688 04 1.673 98 688 04 1,387.21 Unallocated 3 54.340 80 53.09656 22,820 93 54.340.80 22.820 93 52,609 95 Total 83,619.40 80,388.91 36,800.78 83,619.40 36,800.78 79,348.82 S Capital Employed (Segment Assets -Seg ment li::ibilities) Medical and healthcare related services 2 78.841.34 76,771.37 47,257 34 78.841.34 47,257.34 77,866 23 Others 2,063 9 1 1.807.17 1,276 57 2.0639 1 1.276.57 1,697 95 Unallocated 3 (30,851.04) (31,24287) (7,914.96) (30,851.04) (7,914.96) (34,168 96) Total 50,054.21 47,335.67 40,6t8.95 50,054.2 1 40,618.95 45,395.22 1 Includes continuing and discontinued operations 2 Includes Assets classified as held for sale and liabilities directly associated with assets classified as held for sale. 3 Interest on fixed deposits, gain from mutual funds are not allocated to individual segments as the underlying instruments are managed at the corporate level. Similarly investments, fixed deposits, current taxes, deferred taxes and certain financial assets and liabilities are not allocated lo segments as they are managed at the corporate level.
Page 14
\ Narayana Hrudayalaya Limited Registered office : No. 258/A, Bommasandra IDdustrial Area, Anekal Taluk, Bengaluru 560 099, Karnataka, India Corporate office :8th & 9th Floor, No. 84, Phase 1, West Avenue - I, Electronics City, Bengaluru - 560100, Karnataka, India CIN: L851 I0KA2000PLC027497 , Website: www.narayanahealth .org, Email: investorrelations@narayanahcalth.org STATEMENT OF UNAUDITED CONSOLIDATED FINANC IAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2026 The Board of Directors of the Company at its meeting held on 29 November 2024 approved the Scheme of Arrangement for the Merger of Meridian Medical Research & Hospital Ltd. ('MMRHL'), the subsidiary ('Transferor Company ') with the Company ('Transferee Company') and their respective Shareholders and Creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 20 13 ('the Scheme') with I April 2024 as the appointed date and have recommended I (One) equity share of the Company to the shareho lders ofMMRHL (other than the Company) for every 2 (Two) fully paid-up equity shares ofMMRHL. Th~ Stock Exchanges, BSE and NSE, after reviewing the Scheme filed with them by the Company on 20 December 2024 under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations , 20 I 5, had issued 'No Observation Letter' on 23 June 2025 and 24 June 2025, respectively under the said Regulations and the Scheme was filed with the Hon'ble National Company Law Tribunal, Bengaluru Bench (NCLT) on 27 September 2025. Pursuant to the Order dated 2 December 2025 issued by the Hon' ble NCLT, the meetings of the Creditors and the Shareho lders of the Transferor Company and the Transferee Company were held on 19 January 2026 who have passed the Scheme with more than requisite majority. Post approval by the Creditors and the Shareholders, a Petition along with the voting results has been filed with the Hon'ble NCLT on 23 January 2026. Notices were dispatched to all the Regulatory Authorities for seeking their 'No Objection' with respect to the merger of MMRHL with the Company. The Compan y has received No-Objection Letters from the Regulatory Authorities and basis the hearings, the Final Order by !he Hon 'ble NCLT is expected to be received in due course. Further, there is no impact on results for the quarter and six months ended 30 September 2026. 6 Narayana Vaishno Devi Speciality Hospitals Private Limited (NVDSI-IPL), a wholly owned subsidiary of the Company was running and operating the Shri Mata Vaishno Devi Narayana Superspeciality Hospital at Kakryal near Katra in Jammu which caters to patients across more than 20 different specialties, with radiology, obstetrics & gynaecology, oncology, etc. upto the closing hours of 31 March 2026. Pursuant to the Business Transition Agreement dated 25 March 2026 and the Management Agreement dated 28 March 2025, the business undertaking of Shri Mata Vaishno Devi Narayana Superspeciality Hospital has been transferred on a going concern basis to Shri Mata Vaishno Devi Charitable Society (SMVDCS). Accordingly, with effect from 0 l April 2026, the ownership, operations and control of the Hospital stand vested with SMVDCS, and NVDSHPL continues to provide management and consultancy support in terms of the applicable agreements. Comequent to the aforesaid management agreement, the Company has assessed the carrying value of assets and liabilities to be transferred with recoverable value and written down an amount on' 62.06 million during the year ended 31 March 2025. Consequent to the above, the operations ofNVD are considered as Discontinued operations and the impact of the same is as given below: (~ in Million) sr. No. Particulars Quarter ended Six months ended Year ended 30-Scp-26 30-Jun-26 I 30-Sep-25 30-Sep-26 30-Scp-25 31-Mar-26 Unaudited Unaudited Audited I Income Revenue from operations - 394.27 753.63 1,377.37 Other income - 0.92 2.34 4.83 Totnl income - - 395.19 - 755.97 1,382.20 2 EXPENSES Purchase of medical consumables, drugs and surgical instruments - 153.81 290.06 487.94 Changes in inventories of medical consumables. drugs and surgical instruments - J.91 (103) (I 7.00) (increase) / decrease Employee benefits expense 66.32 130.92 253.32 Professional fees to doctors 75.63 - 149.07 299.83 Other expenses 90.80 - 168.85 309.97 Expenses before depreciation and amorti~ation, finan ce costs and exceptional - - 388.47 - 737.87 1,334 .06 items 3 Ettrnings bcfor-e depr-cciation and umor-Hsation, finance costs and exceptional - - 6.72 - 18.10 48.14 item, (1-2) {EDIT DA) 4 Finance co~ts - 043 0.43 0.61 5 Depreciation and amortisation expe'lsc - 4.23 8.36 16.51 6 Total expe:nse (2+4+5) - - 393.13 - 746.66 1,351.18 7 Profit before tax and excepti onal items (1-6) - - 2.06 - 9.31 31.0i s Exceptionnt item - - (5.85) 9 P,·ofit before tax (7+8) - - 2.06 - 9.31 25.17 JO Tai expense: a) Current Tax Current perioc.ltycar - - - 0.69 7.91 b) Deferred tax charge/ (credit) - Tot11I t11x e:1.pcnse - - 0.69 7.9 1 II Pr-ofit from discontinued opentt ions after tn;tes (9- 10) - 2.06 - 8.62 17.26 12 Othcr-Compr-chensive Income: from discontinued ope r-atio ns Items that will not be reclassified subsequently to profit or loss (i) Re-measurement gains/ (losses) on de.tined benefil plans - (0,52) (0.54) (0.18) (ii) Income tax effect - - - Other Comprehensive Jncome/ (losses), net of laxes from discontinued operalions - - (0.52) - (0.54) (0. t 8) 13 Total comprehensive income (11+12) ~KUi........_ - - 1.54 - 8,08 17.08 ~§~\ '('~\~?~}tq/ ,._ ,-: • - <$> o CHARTERED t; fb' , ' ... 'Ii, :.L,.. I iii ACCOUNTANTS ,_} .c:- / \ 01 co • :, 1 C) ,._ ;;,,.', 't> •- . / *~ * ~ 'li,'11,, ,/,.!l ~NGALU~~ l:>'V•---- ··0v - * \) .- --
Page 15
\ Narayana Hrudayalaya Limited Registered office: No. 258/A, Bommasandra Industrial Arca, Anekal Talnk, Bengaluru 560 099, Karnataka, India Corporate office :8th & 9th Floor, No. 84, Phase 1, West Avenue - 1, Electronics City, Bengaluru - 560100, Karnataka , India CIN: L85110KA2000PLC027497, Website: www.narnyanahcalth.org, Email: investorrelations@narayanahealth.org STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2026 7 The Board of Directors of the Company at the meeting held on 12 December 2025 had approved the Scheme of Arrangement between NH Integrated Care Private Limited (NHIC) (Wholly Owned Subsidiary) ['Demerged Company'], Narayana Hrudayalaya Limited ('Resulting Company') and their respective shareholders and creditors to demerge the clinical services as defined in the scheme ofNHIC ('the Demerged Undertaking') into the Resulting Company, while continuing the Narayana Aarogyam Vertical within NHIC, on a going concern basis under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ('the Scheme') with I April 2025 as the Appointed Date. The Scheme was filed with the NCLT, Bengaluru Bench on 17 December 2025. Pursuant to the Order dated 13 February 2026 issued by the Hon' ble NCLT, the meetings of the Creditcrs and the Shareholders of the Demerged Company and the Resulting Company were held on 2 April 2026 who have passed the Scheme with more than requisite majority. Post approval by the Creditors and the Shareholders, a Petition along with the voting results has been filed with the Hon 'ble NCL Ton 8 April 2026. There will be no issuance of shares as consideration, in view of the Demerged Company being a wholly-owned subsidiary of the Resulting Company . The Company is in the process of obtaining the requisite No-Objection Certificates ('NOC') from the Regulatory Authorities. Upon receipt of No-Objection letters from the Regulatory Authorities and basis the hearings, the Final Order by the Hon'ble NCLT is expected to be received in due course.There is no impact on the financial results of the Company for the quarter and six months ended 30 September 2026. 8 On 21 November 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relation s Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "La bour Codes"). These Labour Codes consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during and post-employment. The Labour Codes amongst other things introduced changes including a uniform definition of wages and enhanced benefit to leave. The Group had assessed the financial implicat ions of these changes which had resulted in increase in gratuity liability and leave liability arising out of past service cost by~ 509.54 million in the year ended 31 March 2026. As the impact arises from the enactment of new legislation and is considered non-recurring m nature, the Group has presented this incremental amount under "Exceptional Item". 9 The Consolidated balance sheet as at 30 September 2026, the Statement of Consolidated cash flows and disclosure as per regulation 52(4) ofS EBI (Listing obligations and disclosure requirements) regulations, 2015 are provided as annexures to this Statement. IO The consolidated financial result include results of: \ Subsidiaries of Narayana Hrudayalaya Limited (NHL) Narayana Hospitals Private Limited (NHPL) Meridian Medical Research & Hospital Limited (MMRHL) Narayana Vaishno Devi Specialty Hospitals Private Limited (NVDSHPL) Narayana Hrudayalaya Surgical Hospital Private Limited (NHSHPL) Health City Cayman Islands Limited (HCC!) Narayana Health North America LLC (NHNA) Medh3 Al Private Limited (MAIPL) Samyat Healthcare Private Limited (SHPL) 1'.'H Jntegrated Care Private Limited (NHIC) Narayana Health Insurance Limited (NHIL) Athma Healthtech Private Limited (AHPL) Narayana Healthcare North PriYati Limited (NHNPL) w.e.f 16 January 2026 Subsidiaries of Health City Cayman Islands Limited (HCC/) Narayana Holrlings Private Limited (NHDPL) Cayman Integrated Healthcare Limited (CIHL) ENT in Cayman Islands Limited (EICL) Narayana Hrudayalaya UK Ltd (NH UK) w.e.f8 October 2025 Associate of Health City Cayman lsla11ds Limited (HCC/) Reya Health Inc Joint Venture of Health City Cayman Js/u11ds Limited (HCC/) Everhop~ Oncology Private Limited (EOPL) w.e.f 25 April 2025 Subsidiary of Narayana Holdings Private Limited (NHDPL) NH Health Bangladesh Private Limited (NHBPL) Subsidiary of Everlwpe Oncology Private Limited (EOPL) Samvaya Oncology Private Limited (SOPL) w.e.f 18 June 2025 Subsidiaries of Narayana Hrudayalaya UK Ltd (NH UK) Practice Plus Group Hospitals Limited (PPG) w.e. f 6 November 2025 Practice Plus Group Property Ltd w.c.f 11 March 2026 Subsidiary of Practice Plus Group Hospitals Limited (PPG) Sheptcn Mallet Health Partnership Limited w.e.f 6 November 2025 / Pla<.:c: Beng~luru Date: 3 0 October 2026 for and on bchalfofthe Board of Directors of Narayana Hrudayalaya Limited \- ), - \ ~ _-.. Dr. Emmanuel Ruper: Mw,.1ging Director & Group CEO
Page 16
Narayana Hruda yalaya Limited Registered office: No. 258/A, Bom1nasandra Industr ial Area. Anekal Taluk. Bengaluru 560099, Karnataka, Indi:i Corporate office :8th & 9th Floor, No. 84, Phase 1, \Vest Avenu e - I , Electronics City, Bengalu rn - 560100, India CTN: L85110KA2000PLC027497, Webs ite: WW\\'.narayanahea1th.org, Ema il: investorre lations@n:1rayanahealth.org STATEMENT OF CONSOLIDATED CASH FLOWS FOR SIX MONTHS ENDED 30 SEPTEMBER 2026 Particulars Cash now from operaling activilies Profil arter tax Connnuing operauons D1scontmued operations Adjust ments : Income lax expense Deprcc1at10n .'.ll"ld amon1sa11on cxpcnSe Interest income Interest income from fioancfa.l asset at :unort1scd cost L1ab1h1ies / Provision no longer required wrincn back Provision/ (reversal) for loss allowance and doub 1fuJ advances Bad r~ewables written off Net loss from financiaJ asset at amortized cost Property usage nght Finance costs Grant income Loss on sale/disposal of Property. plant and equipment (Profit}/Loss on sale of investment Unrealised forei!,'11 exch:lnge (gam)/loss Sh:ire of loss of equi.ty ;:iccoumed investees Operating cash flow before worki n~ rapita l changes Changes in trade receivables Changes 111 mventories Changes m loans. other financial assets and other assets Changes m trade payables, other financial liab1hries and other liabilities Changes in provision Cas h generated from operations Income taxes (paid) / refund received (net) Net cash genernted from operating activities (A) Cas h now fro m invest ing activit ies AcqluSJt1on of Property, plant and equipment (mdu dmg cap1t::d work-mMprogress, intangible assets, Intangible assets under development, capital advances and capiral creditors) Proceeds from sale of property, plant and equipment Investment made in other non current investments Investment for acqu1s1lton of subs idiary and others Proceeds from redemption of Optionally Convemble Debentures (OCD) Purch.i.sc of Short term investments Proceeds from sale of short term investments Investment in bank deposit Proceeds from b:lnk deposits Interest received Net cash (used in) inYt'Sling activ ili.cs ( B) C.ish flow from fin ancin g activities Proceeds from longMterm borrowings Repayment of longMtcnn borrowings Dividend paid on equity share (net of d1V1dcnd received on rreasury shares and uncl.umed divtdend) Payment of mterest and other borrow-ing costs Payment of lease ltab1.h11es Net cash (used in) financin g activities (C) Net in cre:1se/dccrca se in c:i.sh and ca.sh equi\,alcnts (A+B+C) Cash and cash equiYalen ts at the begi.nni.n; of the perio d Effects of exchange gam/(loss) on restatement of foreign currency cash and ca.sh equivalents Cash and cash equhralents at the end of the period "" * Cash and cash eqwv.aknts mclude bank overdrafts that are repayable on demand and fonn an mtcgral part of the Company's cash management Par ticulars Cash on band Balance with banks In current accowits In deposit accounlS (due lo mature w1dun 3 months of lhe acqu1s1t1on date) Less 8:ln k overdraft used for cash management purpose "' Cash a nd cash equivalen ts in the wuement of conso lidated cash flow • Ca.sh and cash equivalents include bank overdrafts that are repayable on demand and form an integral part of the Company's cash management Reeonciliation of liabilities from financ ine activities for the oeriod ended 30 Scote m ber 2026 As at Partku lars 1 April 2026 Proceeds Rena,·ment Borrowings (including current ma1ur1ues and exclude bank ov~rdrafts) 48,565 56 1,411.20 (838 .03) Lease liab11ines 9.914.45 (970.15) Tota l liab ililies from linancim!: activit ies 58,4SO.Ol l,4U.20 (1,808. 18) Re(:ond li.arion of liabilities from financin activities for the riod ended JO Se lternbe r 2025 Asat For the period ended 30 September 2026 {Una udited) 5,084 23 953.1 1 3.190 .30 (369 33) (58.07) (23.04) 215.06 473 6.28 5 3 1 1.835,20 (35 50) 6 82 (8634) 201.95 4309 10,973.80 (3,268 85) (125 32) 1,502.43 1.494 86 (24.17 10,552.75 (824 56 9,728.19 (3,792.09) 36.50 ( 168.71) (266 64) 953 79 (26,418.41) 20,190.01 (1,945 54) 1, 115 61 97.18 (10,198.30) 1,411.20 (838 03) (9 13 26) (897 27) (970.15) (2,207.5 1) (2,677.62) 7,605.73 (48 87) 4,879.24 For the ~rio d ended 30 September 2026 (Unaud ited) 53.0S 4.574,89 343.11 4,971.05 (91 81) 4,879.24 Non cash changes fair value/ other changes fi'orei~n ex.chanec 4 17 40 2,017.41 143.43 2,017.41 560.83 Non cash ch:m es Fair value/ (~ in million ) For the period ended 30 Seplernber 2025 (Unaud ited) 4,543.40 8.62 720.4 8 1,726 14 (142.97) (15291) (761) 124.97 1 40 605 5.31 874 23 (36 40) rs s2 (87 11) (62 89) 17 16 7.556.69 (544 69) (42 8) (13.25) 600.36 100.90 7,695.73 (794.07) 6,901.6<\ (2,765 57) 2.92 (121.13) (146.39) (7,832.68 ) 4,657.33 (870 72) 1,707.51 129.38 (5,239.35) 1,891.94 (2,357 68) (913 95) (407 89) 1300.69) (2,088.27) (425.96 ) 4,471.64 5.08 4,050.76 For the period ended 30 September 2025 (Unaudit~d ) 72.14 3,737 62 325.93 4,135.69 (84.93) 4,050.76 (~ in million) As at 30 Sen 2026 49,556 13 11,105.14 60,6<\1.27 (? in m illion) As at P:111iculars \ Aril202 5 Proc eeds Re a ment other changes Foreign exchange 30 Sc 2025 Borro wings (including current maturihes and exclude bank overdrafts) Lease li.'.lbilities TotaJ liabilities from financin activities ( __) \ 22,158 ll 2.150 16 24,308.47 1,891 94 (2,357 68) (272 92) - - ..2 1,419.65 (JOO 69) 173 99 24 60 1,891.94 (2,658.37) 173.99
Page 17
Narayana Hrudayalaya Limited Registered office : No. 258/A, Bommasa ndra Industrial Area, Anekal Taluk, Bcogaluru 560099, Karnataka, India Corporate Office; 8th & 9th Floor, No. 84, Phase I, West Avenue- l, Electronics City, Bengaluru-560100, Karnataka, India CIN: L85110KA2000PLC02749 7, Website: www.narayanabealth.org, Email: investorrelations@,narayanahealth.org ADDITIONAL DISCLOSURES AS PER REGULATION 52(4) OF SEBI (LIST ING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS , 2015 Quarter ended Six months ended Year ended SI. No. Particulars 30-Sen-26 30-Jun-26 30-Sep-25 30-Sep-26 30-Sep-25 31-Mar-26 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudi ted) (Aud ited) l Debt equity ratio 1.21 1.24 0.58 1.21 0.58 1.29 2 Debt service coverage ratio 2.58 2.23 3.16 2.42 2.83 2.36 3 Interest service coverage ratio 4.55 4.00 7.99 4.29 7 02 4 97 4 Current ratio 2.1 S 2.15 2.20 2.15 2.20 2.15 5 Long tenn debt to working capital ratio 1.83 1.97 1.26 1.83 1.26 2.12 6 Bad debts to accounts receivable ratio . . . * . 7 Current liability ratio 0.25 0.24 0.34 0.25 0.34 0.23 8 Tola! debt to Iota! assets ratio 0.37 0.38 0.28 0.37 0.28 0.39 9 Debtors turnover ratio 3.42 3.95 2.74 6.83 552 13.04 IO Operating margin(%) 19.48% 17.50~0 24.49% 1852 % 23.47% 20.47 % 11 Net profil margin(%) 10.59% 7.72°/o 15.71'% 9.20% 14.42% t0.26~'o 12 Inventory tumover ratio 3.34 3.26 2.92 6.60 5.69 11.45 13 Capilal redemption reserve/Debenrure redemption reserve NA NA NA NA NA NA 14 Net worth(~ in Million) 50.029.39 47,312 .11 40,598 .33 50,029.39 40,598.3 3 45.372.58 15 The Company has not issued any secured listed non-convertible debt securities • Values are insignificant The above computations are derived from continuing operations only. Formulae for computation of ratios are as follows S.no Particulars 1 Debt equity ratio 2 Debt service coverage ratio 3 lnlerest service coverage ratio 4 Current ratio 5 Long tenn debt to working capital ratio 6 Bad debts to accowtts receivable ratio 7 Current liability ratio 8 Total debt to total assets ratio 9 Debtors turnover ratio 10 Operating margin(%) 11 Net profir margin(%) 12 Inventory turnover ratio Formulae Numerator Denominator Debt consist borrowings and lease liabilities Total equity Earnings for debt scrvicc=Eamings before Debt Service=Finance cost+lease payments+principal repayments interest and tax (EBIT) (excluding prepayment and working capital loan) Profit before taxes+Finance cost Finance cost Total current assets Total current liabilities Long tenn borrowings (Including maturities oflong tenn borrowings) current Current assets (-) Current liabilities (Excluding current maturities of long tenn borrowings J Bad debts Average gross trade receivables Total current liabilities Total liabilities Total borrowings Total assets Revenue from operations Average trade receivables Earnings before depreciation,frnance oost,tax and Revenue from operations exceptional items (-) other Income Net profit after taxes Revenue from operations Cost of goods sold= Purchase of medical Average inventory consumables. dnigs, surgical instruments and other consumables+Changes in inventories medical consumables. dnigs, surgical instruments and other constunables
Page 18
Narayana Hrudayalaya Limited Registered office : No. 258/A, Bommasandra Indus tria l Area , Aneka l Taluk, Benga luru 560099 , Karnataka , Ind ia Corporate Office : 8th & 9th Floor, No. 84, Phase 1, West Aven ue - 1, Electro nics City, Bengaluru - 560 100, Karoataka, India CIN: L851 I0KA2000PLC027497, Websi te: www.narayanahea lth.org , Emai l: investorrelatio ns@narayanahealt h.org UNAUDITED CONSOLIDA T£D BALANC E SHEET (fin Million) SI. No. Particulars As at 30 Sep 2026 As at 31 March 2026 (Unaudited) (Audited) A. ASSETS 1. Non- current assets a) Property, plant and equipment 46,405.17 45,266.69 b) Capital work-in-progress 3,279.94 2,668.42 c) Right to use assets 9,595.6 7 8,455.90 d) Goodwill 14,132.75 13,905.60 e) Intangible assets 10,089.15 10,330.11 f) Intangible assets under development 234.55 250.94 g) Investment in associates 495.62 266.28 h) Financial assets i) Investments 1,471.26 1,322.66 ii) Loans - 949.27 iii) Other financial assets 740.25 644.42 i) Income tax assets (net) 170.20 96.00 j ) Deferred tax assets (net) 131.08 112.27 k) Other non-current assets 1,117.95 1,154.12 Sub-tota l- Non-current assets 87,863.59 85,422.68 2. Current assets a) Inventories 1,670.61 1,545.29 b) Financial assets i) Investments 10,45 1.08 4,142.62 ii) Trade receivables 9,618.68 6,556.62 iii) Cash and cash equivalents 4,971.05 7,700.67 iv) Bank balances other than (iii) above 14,426.66 13,591.26 v) Other financial assets 2,702.91 3,839 .58 c) Other current assets 1,969.03 1.945.32 Sub-total- Current assets 45,810.02 39,321.36 TOT AL- ASSETS 1,33,673.61 1,24,744.04 B EQUITY AND LIABILITIES I. Equity a) Equity share capital 2.043 6 1 2,043 .6 1 b) Other equity 47,985.78 43,328 .97 Sub-total- Total eauitv attributable to owners of the Comoanv 50,029.39 45,372.58 2. Non controlling i.nterests 24.82 22.64 Sub-total- Total equity 50,054.2] 45,395.22 3. Non-current liabilities a) Financial liabilities i) Borrowings 46,978 .85 46,671.82 ii) Lease liabilities 9,45 1.17 8,496.20 iii) Other financial liabilities 489.60 486.61 b) Provisions 803.18 749.22 c) Deferred tax liabilities (net ) 3,269.31 3,307.51 d) Other non-current liabilities 1,330.82 1,364.94 Sub-total- Non-current liabilities 62,322.93 61,076.30 4. Current liabilities a) Financial liabilities i) Borrowings 2,669.09 1,988.68 ii) Lease liabilities 1,653.97 1,418.25 iii) Trade payables Total outstandmg dues of micro enterprises and small enterprises 650.3 1 435. 14 Total outstanding dues of creditors other than micro en1erprises and small enterprises I 1,334.25 9,886 .00 iv) Other financial liabilities 1,634.59 1,396.99 b) Other current liabilities 1,949.55 1,940.82 c) Current tax liabilities (Net) 539.52 296.85 d) Provisions 865.19 909.79 Sub-total- Current liabilities 21,296.47 18,272.52 Sub-tota l- Total liabilities 83,619.40 79,348.82 TOTAL- EQUITY AND LlABlLJTIBS 1,33,673.61 1,24,744.04 \